Compositions and Methods for Modulation of SMN2 Splicing in a Subject (2015)
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,717,750 | Compositions and Methods for Modulation of SMN2 Splicing in a Subject In force · Medium confidence | Isis Pharmaceuticals, Inc. | In force | Medium confidence | ||
| Application 15/892,560 | Compositions and Methods for Modulation of SMN2 Splicing in a Subject Abandoned Abandoned Jan 6, 2020 | Biogen Ma Inc. | Abandoned | Abandoned Jan 6, 2020 | ||
| Application 16/708,739 | Compositions and Methods for Modulation of SMN2 Splicing in a Subject Abandoned Abandoned Oct 19, 2021 | Biogen Ma Inc. | Abandoned | Abandoned Oct 19, 2021 |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Isis Pharmaceuticals, Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.